Compare SHIM & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | IMUX |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 155.8M |
| IPO Year | 2023 | 2013 |
| Metric | SHIM | IMUX |
|---|---|---|
| Price | $2.30 | $7.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $7.00 | ★ $43.09 |
| AVG Volume (30 Days) | 95.3K | ★ 382.7K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.95 | 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $492,844,000.00 | N/A |
| Revenue This Year | $1.41 | N/A |
| Revenue Next Year | $20.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.63 | N/A |
| 52 Week Low | $1.95 | $0.51 |
| 52 Week High | $6.76 | $17.43 |
| Indicator | SHIM | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 27.89 | 36.21 |
| Support Level | N/A | $6.35 |
| Resistance Level | $4.09 | $8.60 |
| Average True Range (ATR) | 0.18 | 0.65 |
| MACD | -0.03 | 0.19 |
| Stochastic Oscillator | 15.03 | 46.67 |
Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.